TL27: The Interface between Statistical and PKPD Modeling and Simulation
Dionne Price, CDER, FDA *Matthew David Rotelli, Eli Lilly and Company Keywords: PKPD, Modeling, Simulation, Acceleration, Collaboration The fields of statistics and PKPD have made tremendous advancements in the last two decades toward accelerating drug development through innovative study designs and model based drug development. While there has been some great collaboration in method development, and isolated examples of integration in practice, generally these groups work in silos and confusion, skepticism and mistrust among practitioners limit realization of the potential synergies of these combined fields. The goal of this round table discussion will be to identify areas of modeling and simulation where better cross education, communication, and collaboration can remove barriers or further enhance drug development. Venues for scientific sessions, workshops, and symposia to address the identified topics will also be discussed.
|
Key Dates
-
June 3, 2014 - September 7, 2015
Online Registration -
June 3, 2015 - August 15, 2015
Housing -
July 31 - August 17, 2015
Invited Abstract Editing -
August 10, 2015
Short Course materials due from Instructors -
August 26, 2015
Advanced Registration Deadline -
September 7, 2015
Cancellation Deadline -
September 16 - 18, 2015
Marriott Wardman Park, Washington, DC